Certara’s Post

Artificial intelligence/machine learning (AI/ML) are increasingly being utilized in drug development. As pharmaceutical companies incorporate these new technologies, it is critical to understand their current strengths and limitations and how their use will be viewed by regulatory agencies. Join us for a webinar addressing those challenges, featuring guest presenter Dr. Qi Liu, Associate Director for Innovation & Partnership at the Office of Clinical Pharmacology/Office of Translational Sciences at the Center for Drug Evaluation and Research (CDER). Gain insights into AI/ML fundamentals, regulatory submissions at CDER/FDA, and real-world examples of review and research. Understand key challenges and regulatory considerations to effectively leverage AI/ML in drug development. Don’t miss this opportunity. Register to join us. https://lnkd.in/grFKUbu9

Thank you, Frank Kumli, for sharing this exciting report! Generative AI will transform pharmaceutical research and development by strengthening #innovation, offering #cost efficiencies, and speeding the traditionally ponderous research-to-market cycle. Successes and advancements in AI have led to wider adoption, integration, and new applications of the technology in drug development. Notably, pharmaceutical companies' are increasingly using generative AI to facilitate the creation of new molecular structures and drug compounds. AI is also facilitating analysis of #RWD for existing treatments, improving companies' potential to file for additional indications. And traditional pharmaceutical companies now often collaborate with specialist AI-driven pharma-tech companies to build healthcare platforms. ---- OM1, Inc. Polaris, powered by PhenOM™, a digital phenotyping AI platform for personalized medicine and clinical research, optimizes clinical trial recruitment by leveraging real-world data, predicted outcomes, and protocol-tailored phenotypic profiles to identify prospective patients, investigators, and sites. https://lnkd.in/evZGcwdf Full Report: https://lnkd.in/eFE7P88x #innovation #bigdata #rwd #realworlddata #drugdevelopment #pharma #access #marketaccess #heor #patientjourney #healthcare #biopharma #ml #drugdiscovery #clinicaltrials #predictiveanalytics #personalizedmedicine #rwe #realworldoutcomes #realworldevidence

Delve into the cutting-edge applications of generative AI in clinical research!🔬 Explore the applications of generative AI in medical data analysis, treatment optimization, and drug discovery. Gain insights into the potential of AI-driven technologies to enhance clinical decision-making, improve patient recruitment and retention, and enable precision medicine approaches. https://hubs.li/Q02f0Kjv0 #CTMS #eTMF #EDC #RTSM #Safety #PV #Pharmaceutical #Biotechnology #MedicalDevices #Diagnostics #Cloudbyz #ClinicalTrial #GenerativeAI #Innovation #DigitalTransformation

https://lnkd.in/drqZ7ES6 Artificial intelligence (AI) is revolutionizing the pharmaceutical industry, driving advancements in drug discovery and development. A recent review from NIPER-A, led by Debleena Paul and colleagues, underscores AI's pivotal role in drug design, repurposing, and clinical trials. Through machine learning and deep learning, AI efficiently analyzes vast datasets, optimizes drug structures, and predicts properties and toxicity, streamlining drug screening and formulation design processes. Moreover, AI contributes to enhanced clinical trial design by refining patient selection and adherence strategies. Despite challenges like data accessibility and the demand for skilled professionals, the pharmaceutical AI market is expected to soar to $5 billion by 2024.

Artificial intelligence (AI) is reshaping the pharmaceutical industry, spearheading breakthroughs in drug discovery and development. A recent review highlights AI's crucial impact on drug design, repurposing, and clinical trials. Through machine learning and deep learning, AI accelerates data analysis, optimizes drug structures, and forecasts properties and toxicity. This streamlines drug screening and formulation processes, while boosting clinical trial designs. Challenges remain, such as data accessibility and skilled workforce demand, but the pharmaceutical AI market is projected to reach $5 billion by 2024. Let's embrace the future of AI in healthcare!

Exciting advancements in artificial intelligence (AI) and machine learning (ML) are reshaping industries worldwide, and the pharmaceutical sector is no exception. In fact, we've witnessed a remarkable surge in drug and biologic submissions integrating AI/ML components, with over 100 submissions in 2021 alone. The convergence of AI and pharmaceuticals holds immense promise for innovation and efficiency in drug development. https://ow.ly/oHe130sCpWH #AI #MachineLearning #Pharmaceuticals #Innovation #DrugDevelopment

Explore the Future of Pharma with EPR's groundbreaking report on Artificial Intelligence! 💊 Discover the cutting-edge advancements in AI and ML transforming drug development, manufacturing, and quality control in the pharmaceutical industry. Join us as we unpack the challenges and opportunities of AI in Pharma with insights from industry leaders including Dr. Feng Ren from Insilico Medicine, Dr. Andrew Hopkins of Exscientia, Tero Laulajainen from UCB, legal expert Vincenzo Salvatore, microbiology guru Dr. Tim Sandle, Ph.D., CBiol, FIScT, and experienced QP Phoebe Clough. Download the report for free >> https://bit.ly/3S2Y6yw #PharmaHorizons #ArtificialIntelligence #AI #ML #Pharmaceutical

“AI in Pharmaceutical Supply Chains and Manufacturing - with Laks Pernenkil of Deloitte” https://lnkd.in/e9xbFbgd The field of drug development and clinical trials is rapidly evolving towards a personalized, data-centric approach, necessitating the adoption of sophisticated artificial intelligence (AI) solutions. These AI technologies are critical not only for streamlining clinical trials and enhancing drug development but also for broader applications such as demand forecasting, quality control, and optimizing the supply chain. The effective use of AI is increasingly becoming a cornerstone for pharmaceutical companies aiming to maintain and improve their competitive advantage through superior supply chain management. In a noteworthy conversation, CEO and Head of Research at Emerj Artificial Intelligence Research Daniel Faggella and Laks Pernenkil, Life Sciences Principal at Deloitte, delved into the transformative impact of AI and data analytics on the supply chain within the life sciences sector. #AI #DataAnalytics #Pharmaceuticals #ClinicalTrials #DrugDevelopment #SupplyChainManagement #MachineLearning #GenerativeAI #QualityControl #DemandForecasting #LifeSciences #Innovation #StrategicInvestment #OperationalEfficiency #PatientCare

Exciting advancements in artificial intelligence (AI) and machine learning (ML) are reshaping industries worldwide, and the pharmaceutical sector is no exception. In fact, we've witnessed a remarkable surge in drug and biologic submissions integrating AI/ML components, with over 100 submissions in 2021 alone. The convergence of AI and pharmaceuticals holds immense promise for innovation and efficiency in drug development. https://ow.ly/JjX930sClHr #AI #MachineLearning #Pharmaceuticals #Innovation #DrugDevelopment